Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.75 GBX | 0.00% | 0.00% | -53.12% |
04-26 | Evgen Pharma plc will Change its Ticker to TCF from EVG | CI |
04-26 | Evgen Pharma plc will Change its Name to TheraCryf plc | CI |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- One of the major weak points of the company is its financial situation.
- The company's enterprise value to sales, at 2.1 times its current sales, is high.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-53.12% | 4.01M | - | ||
+3.91% | 109B | B+ | ||
+10.87% | 105B | B+ | ||
+1.28% | 22.25B | B | ||
-13.14% | 22.09B | B+ | ||
-7.05% | 18.68B | A- | ||
-38.36% | 17.58B | A- | ||
-10.66% | 16.85B | B | ||
+3.75% | 13.76B | C+ | ||
+36.70% | 12.46B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- EVG Stock
- Ratings Theracryf Plc